TY - JOUR
T1 - Effect of human albumin on TCD vasospasm, DCI, And cerebral infarction in subarachnoid hemorrhage
T2 - The Alisah study
AU - Suarez, Jose I.
AU - Martin, R. H.
AU - Calvillo, E.
AU - Bershad, E. M.
AU - Venkatasubba Rao, C. P.
N1 - Funding Information:
ALISAH was funded by the NIH/NINDS (R01NS049135; PI: Suarez JI).
Publisher Copyright:
© Springer International Publishing Switzerland 2015.
PY - 2015
Y1 - 2015
N2 - Background and Purpose: The neuroprotective effects of human albumin have been studied in animal models of stroke and in humans with various intracranial disorders. We investigated the effect of 25% human albumin (ALB) on mean cerebral blood fl ow velocities (MCBFV), delayed cerebral ischemia (DCI), and cerebral infarction. Methods: We studied patients from the Albumin in Subarachnoid Hemorrhage (ALISAH) pilot clinical trial. We collected data on MCBFV as measured by transcranial Doppler ultrasound (TCD), incidence of DCI, and cerebral infarctions on head computed tomography (CT) scan at 90 days. Results: TCD showed vasospasm in 75% (n = 15), 55% (n = 11), and 29% (n = 2) of subjects in dosage tiers 1, 2, and 3, respectively. DCI was present in 20% (n = 4), 15% (n = 3), and 14% (n = 1) of subjects in dosage tiers 1, 2, and 3, respectively. Cerebral infarctions were seen in 45% (5 of 9), 27% (3 of 18), and 25% (1 of 4) of subjects who had followup head CT scans in dosage tiers 1, 2, and 3, respectively. Conclusions: Higher dosages of ALB were associated with a lower incidence of TCD vasospasm, DCI, and cerebral infarction at 90 days in a dose-dependent manner.
AB - Background and Purpose: The neuroprotective effects of human albumin have been studied in animal models of stroke and in humans with various intracranial disorders. We investigated the effect of 25% human albumin (ALB) on mean cerebral blood fl ow velocities (MCBFV), delayed cerebral ischemia (DCI), and cerebral infarction. Methods: We studied patients from the Albumin in Subarachnoid Hemorrhage (ALISAH) pilot clinical trial. We collected data on MCBFV as measured by transcranial Doppler ultrasound (TCD), incidence of DCI, and cerebral infarctions on head computed tomography (CT) scan at 90 days. Results: TCD showed vasospasm in 75% (n = 15), 55% (n = 11), and 29% (n = 2) of subjects in dosage tiers 1, 2, and 3, respectively. DCI was present in 20% (n = 4), 15% (n = 3), and 14% (n = 1) of subjects in dosage tiers 1, 2, and 3, respectively. Cerebral infarctions were seen in 45% (5 of 9), 27% (3 of 18), and 25% (1 of 4) of subjects who had followup head CT scans in dosage tiers 1, 2, and 3, respectively. Conclusions: Higher dosages of ALB were associated with a lower incidence of TCD vasospasm, DCI, and cerebral infarction at 90 days in a dose-dependent manner.
KW - Clinical trials
KW - Delayed cerebral ischemia
KW - Human albumin
KW - Subarachnoid hemorrhage
KW - Transcranial Doppler ultrasound
UR - http://www.scopus.com/inward/record.url?scp=84921726688&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84921726688&partnerID=8YFLogxK
U2 - 10.1007/978-3-319-04981-6_48
DO - 10.1007/978-3-319-04981-6_48
M3 - Article
C2 - 25366638
AN - SCOPUS:84921726688
SN - 0065-1419
VL - 120
SP - 287
EP - 290
JO - Acta Neurochirurgica, Supplementum
JF - Acta Neurochirurgica, Supplementum
ER -